The architecture powering Zero Trust at the edge

Tern plc

The shift to Zero Trust security has placed a new spotlight on the most fundamental yet overlooked layer of the digital ecosystem: device identity. For enterprises managing vast fleets of connected assets, the moment of onboarding is no longer a technical footnote, it is the critical juncture where long-term trust, compliance, and resilience begin.

What has long been treated as an administrative step in the supply chain has now become a strategic control point. Weak or reused device identities have been the unseen entry point for some of the most serious operational breaches, from energy grid outages to compromised medical systems. Yet, the tide is turning. Advances in automated identity provisioning now enable enterprises to establish verifiable trust at the very edge, embedding security directly during manufacturing and onboarding rather than layering it on afterwards.

At the centre of this evolution is Device Authority’s KeyScaler® platform, which automates the creation and management of strong, unique device identities at industrial scale. Each identity can be anchored in hardware through Trusted Platform Modules or secure elements, or dynamically generated via Dynamic Device Key Generation when such components are absent.

The true strength of Zero Trust, however, lies in the ongoing validation of identity rather than its initial establishment. Device Authority’s partnership with Olympus integrates these trust anchors into identity and access management frameworks where policies continuously adapt to device health, behaviour, and operational context.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines uses AI to turn medical congress discussions into pharma insights

Talking Medicines uses AI to analyse healthcare professional conversations at medical congresses, turning discussions into structured insights that help...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

Device Authority warns supermarket freezer cyberattack exposes connected device security risks

Device Authority warns that a cyberattack affecting around 700 French supermarkets exposes security weaknesses in connected industrial equipment and...

Breast cancer research highlights importance of patient intelligence in pharma

Talking Medicines highlights how AI-powered patient intelligence can help pharmaceutical companies understand breast cancer treatment experiences and identify unmet...

GLP-1 drugs linked to emerging research into mental health and addiction

Research into GLP-1 medicines is expanding beyond weight loss, with studies examining potential links to depression, cognitive function, alcohol...

Talking Medicines examines emerging links between GLP-1 drugs and mental health

Researchers are investigating the potential links between GLP-1 medicines and mental health, with early findings prompting further studies into...

Search